title: Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
abstract: To identify factors associated with relapse-free survival (RFS), 80 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, enrolled in a phase II study of imatinib-combined chemotherapy, were analyzed. The median follow-up of surviving patients was 26.7 months (maximum, 52.5 months). Twenty-eight out of 77 patients who had achieved CR relapsed. The probability of RFS was 50.5% at 2 years. Multivariate analysis revealed that the presence of secondary chromosome aberrations in addition to t(9;22) at diagnosis constitute an independent predictive value for RFS (p=0.027), and increase the risk of treatment failure by 2.8-fold.
authors.affiliation: Nagoya University Graduate School of Medicine, Nagoya, Japan. myanada@mdanderson.org
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Yanada
authors.forename: Jin
authors.initials: J
authors.lastname: Takeuchi
authors.forename: Isamu
authors.initials: I
authors.lastname: Sugiura
authors.forename: Hideki
authors.initials: H
authors.lastname: Akiyama
authors.forename: Noriko
authors.initials: N
authors.lastname: Usui
authors.forename: Fumiharu
authors.initials: F
authors.lastname: Yagasaki
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nishii
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Ueda
authors.forename: Makoto
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Shuichi
authors.initials: S
authors.lastname: Miyawaki
authors.forename: Atsuo
authors.initials: A
authors.lastname: Maruta
authors.forename: Hiroto
authors.initials: H
authors.lastname: Narimatsu
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Shigeki
authors.initials: S
authors.lastname: Ohtake
authors.forename: Itsuro
authors.initials: I
authors.lastname: Jinnai
authors.forename: Keitaro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Tomoki
authors.initials: T
authors.lastname: Naoe
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Ohno
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001549:Benzamides; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D011237:Predictive Value of Tests; D011743:Pyrimidines / Q000008:administration & dosage*; D012008:Recurrence; D015996:Survival Rate; D014184:Transplantation, Homologous
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate